February 26, 2026 argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
February 26, 2026 argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
February 19, 2026 argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
Follow us
Get the latest news and info via our social media channels.